Across the world, women live longer than men. The reason behind the difference between male and female life expectancy is unclear, but it seems related partially to biological advantages and partially to environmental and behavioral factors. Even though women outlive men, they are more prone to suffering from ill health and other age-related diseases. Women's healthcare, however, especially in less-developed settings, remains mostly confined to reproductive issues, particularly maternal health. Attention to other significant women’s health issues, such as oncology, reproductive health, and urology, is growing rapidly.
Overall, advancements in women’s health diagnostic products are intense, and diagnostic technologies have been subjected to rapid change. Two key market drivers are the rising occurrence of lifestyle disorders among women and growing awareness of women-specific health issues. The other drivers include the rise in the number of private diagnostic labs (mostly in emerging nations), health initiatives/drives taken by governments and other health organizations, and new approvals for easy-to-use rapid tests. Nevertheless, the lack of skillful lab professionals and high set-up costs of diagnostic devices/systems are some key growth restraints in the women’s health diagnostics market.
Currently, women’s health diagnostic products are being targeted at markets outside of traditional hospitals or clinical laboratories. The demand for home healthcare services in women’s health is facing a steady increase; however, at the same time, there is pressure to lower costs and maintain the high quality of the care delivered at home. Continuous improvements in technology are bringing about a number of new diagnostic tests that consolidate high levels of accuracy with rapid, easy-to-use product designs.
A gradual rise in infertility rates because of stressful lifestyles is triggering growth in the global pregnancy and fertility testing market. Additionally, point-of-care testing (POCT) devices that monitor ovulation and detect pregnancy are easy to use and cost effective, which are key propelling factors for the POCT market. Prenatal genetic tests that are predominantly used to test disorders, such as aneuploidies in chromosomes 21, 18, and 13 and carrier screens, are gaining momentum because of enhanced assay outcomes through non-invasive methodologies, increased popularity through social media channels, and the growing number of women choosing to become pregnant at an advanced age.
This strategic research service provides key growth drivers as well as the current competitive landscape in the women's reproductive health diagnostics market. In addition, this service covers the market size and growth rate forecast for 2016 and 2021. The scope of the study includes the women's reproductive health diagnostics market, which has been categorized into POC/molecular tests, lab instrumentation, and surgical instruments.
Key Questions This Study Will Answer:
What are the key market opportunities that make this an attractive market, with a significant future revenue potential for companies?
What is the growth potential for women’s reproductive health diagnostics solutions as well as the sub-segments across different geographies?
What are the key growth drivers that companies should focus on to remain relevant and competitive in this market?
Which are the top game-changing companies in women’s reproductive health diagnostics, and what are their leading product portfolios?